AndrewMBrunnerMD

PubMed

• 43 citations
  Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy.
  Areej El-Jawahri, Gregory A. Abel, Lara Traeger, Lauren Waldman, Netana Markovitz
  Leukemia. 2019-03-28
• 107 citations
  Health care utilization and end-of-life care for older patients with acute myeloid leukemia
  Areej El-Jawahri, Gregory A. Abel, David P. Steensma, Thomas W. LeBlanc, Amir T. Fathi
  Cancer. 2015-08-15
• 104 citations
  Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort
  Maximilian Stahl, Michelle DeVeaux, Pau Montesinos, Raphael Itzykson, Ellen K. Ritchie
  Blood Advances. 2018-04-24

Journal Articles

• Effectiveness of Integrated Palliative and Oncology Care for Patients with Acute Myeloid Leukemia  
  Areej El-Jawahri, Thomas W Leblanc, Selina M Luger, Bhavana Bhatnagar, Alison R Walker, Amir T Fathi, Andrew M Brunner, Gabriela S Hobbs, Jennifer S Temel, JAMA Oncology

Abstracts/Posters

• Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic...
  Andrew M. Brunner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3-ITD: Results from an International Collaboration
  Andrew M. Brunner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Sy...
  Andrew M. Brunner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Na¥ve Patients with Relapsed or Refractory My...
  Andrew Brunner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodyspl...
  Andrew Brunner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
  Andrew Brunner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Quality of Life and Psychological Distress in Patients with Acute Myeloid Leukemia (AML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Phase I Study of the Antibody-Drug Conjugate Brentuximab Vedotin Combined with Re-Induction Chemotherapy in Patients with CD30-Expressing Relapsed/Refractory Acute Mye... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018